Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLACENTEX intramuscular treatment for cutaneous lesions in scleroderma
2015-005100-28Phase 4Terminated
- Sponsor
- Mastelli
- Start
- Jan 2022
- Modality
- Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of LAENNEC in morphea and scleroderma, sponsored by Mastelli. Primary endpoint: Clinical improvement of cutaneous lesions. Started Jan 2022; status: terminated.
02
Drugs
LAENNEC
03
Conditions
morpheascleroderma
Beyond the preview
Go deeper on 2015-005100-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005100-28.